Selumetinib: a selective MEK1 inhibitor for solid tumor treatment
Crossref DOI link: https://doi.org/10.1007/s10238-021-00783-z
Published Online: 2022-02-16
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hedayat, Mohaddeseh
Jafari, Reza
Majidi Zolbanin, Naime http://orcid.org/0000-0001-7286-5319
Text and Data Mining valid from 2022-02-16
Version of Record valid from 2022-02-16
Article History
Received: 10 July 2021
Accepted: 7 December 2021
First Online: 16 February 2022
Declarations
:
: The authors have no conflicts of interest to declare that are relevant to the content of this article.